Beigene Ltd (BGNE) Trading Down 1.6%
Beigene Ltd (NASDAQ:BGNE)’s share price dropped 1.6% during mid-day trading on Monday . The company traded as low as $28.58 and last traded at $29.07, with a volume of 52,973 shares trading hands. The stock had previously closed at $29.54.
BGNE has been the subject of a number of research analyst reports. Morgan Stanley increased their price target on shares of Beigene from $39.00 to $42.00 in a report on Friday, April 8th. Cowen and Company reiterated an “outperform” rating on shares of Beigene in a report on Thursday, March 31st. Finally, Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a report on Monday, May 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $39.67.
The firm’s market capitalization is $649.82 million. The firm’s 50-day moving average is $30.05 and its 200-day moving average is $28.98.
Beigene (NASDAQ:BGNE) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.92. The business had revenue of $0.70 million for the quarter. The firm’s revenue for the quarter was down 50.0% compared to the same quarter last year. Analysts anticipate that Beigene Ltd will post ($3.17) earnings per share for the current fiscal year.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.